Phesgo patient information leaflet
WebThe Northern Cancer Alliance prioritises work to streamline and improve the cancer pathways. This ‘pathway’ typically includes the following stages: Referral into services Investigation(s) Diagnosis Treatment Follow up and living with and beyond cancer support Some of these steps will take place within the same hospital/clinical setting, some will … WebPHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body …
Phesgo patient information leaflet
Did you know?
WebRedirecting to /treatment/targeted-therapy/phesgo (308) WebMost common side effects of PHESGO and tips you can try. The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are hair loss, nausea, diarrhea, low levels of red blood cells, and weakness. The most common side effects of PHESGO when given with docetaxel for treatment of breast cancer that has …
WebPatient leaflet - Phesgo Package leaflet: Information for the user Phesgo 600 mg/600 mg solution for injection Phesgo 1200 mg/600 mg solution for injection … WebPhesgo (‘f-ehz-go’) is a treatment which has been created to treat HER2-positive breast cancer. Phesgo is made up of two drugs, called pertuzumab (‘pert-ooz-oo-mab’) and …
WebPhesgo® contains two separate monoclonal antibodies, trastuzumab and pertuzumab. Previously, trastuzumab and pertuzumab were used separately or in combination to … WebOct 9, 2024 · The most important aspect of the GMC guidance is that information about risk must be individualised for that patient. So for example, risk of cardiac events may be higher in a patient with pre-existing cardiac disease, or peripheral neuropathy may be more relevant if you are a concert pianist, as opposed to a patient who is not.
WebMar 2, 2024 · Phesgo is a cancer medicine for treating adults with ‘HER2-positive’ breast cancer (where a protein called HER2 is found on the cancer cells). It is used in …
WebPhesgo® contains pertuzumab, trastuzumab, and hyaluronidase-zzxf. It is best to read this information with our general information about breast cancer. These treatments belong … gvhd of the liver symptomsWebPhesgo 1200 mg/600 mg/30,000 units (providing 1200 mg pertuzumab, 600 mg trastuzumab and 30,000 units hyaluronidase per 15 mL) single-dose vials: 50242-0245-xx Phesgo 600 mg/600 mg/20,000 units (providing 600 mg pertuzumab, 600 mg trastuzumab and 20,000 units hyaluronidase per 10 mL) single-dose vials: 50242-0260-xx VII. … gvhd of the gut symptomsWebMar 16, 2024 · The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. Last updated on emc: 16 Mar 2024. This medicinal product is subject to … gvhd of the skinWebIndications Early Breast Cancer. PHESGO ® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for. the neoadjuvant … gvhd ophthalmologyWebMar 18, 2024 · Phesgo 600 mg/600 mg solution for injection Active Ingredient: trastuzumab, pertuzumab Company: Roche Products Limited See contact details ATC code: L01XY02 … gvhd physical therapyWebNov 1, 2024 · Phesgo is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior … gvhd of the jointsWebPHESGO administration can result in serious and fatal pulmonary toxicity. Discontinue PHESGO for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory … gvhd orphan